Affimed
Yahoo Finance • last year
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024.Acimtamig: Received fast-track designation for the combination of acimtamig and All... Full story
Yahoo Finance • last year
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc... Full story
Yahoo Finance • last year
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third... Full story
Yahoo Finance • last year
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Addition of Affimed’s innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells with ICE®ICE® combined with NK cells o... Full story
Yahoo Finance • last year
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a 72.2% complete response rate as of the... Full story
Yahoo Finance • last year
Affimed to Participate in Upcoming Investor Conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announc... Full story
Yahoo Finance • last year
Affimed Announces Listing Transfer to Nasdaq Capital Markets
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to... Full story
Yahoo Finance • last year
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou... Full story
Yahoo Finance • last year
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed/refractor... Full story
Yahoo Finance • last year
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation pH Leveraging the full potential of FcRn... Full story
Yahoo Finance • 2 years ago
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno... Full story
Yahoo Finance • 2 years ago
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and has been accepted for poster presentationAn enc... Full story
Yahoo Finance • 2 years ago
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentationA trial in progress abstract of the phase 1 dose escalation study t... Full story
Yahoo Finance • 2 years ago
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentation AFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online publication HEIDELBERG, Germany, Apri... Full story
Yahoo Finance • 2 years ago
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
Affimed N.V. The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cells It demonstrates the potential of AFM13 to induce serial killing, even in tumor cells with low ta... Full story
Yahoo Finance • 2 years ago
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) population Patients with Angioimmunoblastic T cell lymphoma (AITL), o... Full story
Yahoo Finance • 2 years ago
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed N.V. HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has... Full story
Yahoo Finance • 2 years ago
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the first patient... Full story
Yahoo Finance • 2 years ago
Affimed Reports 2022 Financial Results and Operational Progress
AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expe... Full story
Yahoo Finance • 2 years ago
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) A poster presentation from the col... Full story
